查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1726154

神經生物標記市場規模、佔有率、趨勢分析報告：按應用、類型、最終用途、地區和細分市場預測，2025 年至 2030 年

Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), By Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

神經生物標記市場的成長和趨勢

根據 Grand View Research, Inc. 的新報告，全球神經生物標記市場預計到 2030 年將達到 187.5 億美元，2025 年至 2030 年期間的複合年成長率為 12.9%。

增加對神經生物標記研究和開發的資金以促進開發新藥預計將推動市場成長。美國國家神經疾病和中風研究所為進行臨床檢驗、分析檢驗和生物標記發現相關研究的研究人員提供資助機會，包括合作研究協議和研發津貼。

生物標記在神經系統疾病治療的發展中發揮重要作用。近年來，對神經系統疾病治療方法研究和開發的投入顯著增加。例如，2020年12月，非營利研究基金會Target ALS宣布將為專注於發現ALS新型生物標記的計劃提供1,500萬美元的研究資金，預計這將在預測期內加速市場成長。

Quanterix Simoa（單分子陣列）等技術先進的產品的出現，這是一種具有高信噪比的數位化ELISA 測試。這項技術有助於克服與神經系統疾病相關的生物標記相關的血腦障壁問題。預計此類技術進步將推動市場成長。例如，2021 年 1 月，雅培宣布推出首個針對創傷性腦損傷（包括腦震盪）的快速血液檢測。此測試測量腦外傷後血液中發現的某些蛋白質，如果測試結果為陰性，則可用於排除進行電腦斷層掃描的必要性。

對此類診斷產品的認知度低、成本高以及神經科短缺或缺失等因素（尤其是在新興和低度開發國家）可能會影響此類基於生物標記的診斷解決方案的採用。根據世界神經病學聯合會對世界衛生組織84個成員國中的63個成員國進行的調查，63個國家中的31個國家的神經科大多在大城市工作。每位神經科服務的人口約為 6,240 至 4,750,000。

神經生物標記市場報告重點

  • 2024年，蛋白質體學將佔據最大的市場佔有率，並預計在預測期內保持其主導地位。蛋白質體學方法對於準確診斷疾病的發生和進展至關重要，因為它們可以仔細檢測轉譯後修飾和蛋白質特徵。
  • 由於患病率上升和研發活動活性化，帕金森氏症領域佔據了最大的市場佔有率。
  • 根據最終用途，研究機構和其他部門主導了神經生物標記市場。合作開發神經系統疾病治療方法的研究機構正在使用生物標記來評估抗藥性。
  • 由於美國和加拿大市場參與企業實力雄厚，且政府對新型生物標記開發的資助不斷增加，北美在市場中佔據主導地位。
  • 由於日本和澳洲等已開發經濟體廣泛採用技術先進的診斷產品，並且中國和印度等新興經濟體擴大採用這些產品，預計亞太地區將在預測期內顯著成長。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章 神經生物標記市場變數、趨勢與範圍

  • 神經生物材料市場的系統性概述
    • 母市場展望
  • 滲透和成長前景圖
  • 管道分析
    • 阿茲海默症
    • 帕金森氏症
    • 多發性硬化症
    • 泛自閉症障礙
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 神經生物標記：市場分析工具
    • 產業分析—波特五力分析
    • PESTLE分析

4. 神經生物標記市場：細分分析（按類型），2018-2030

  • 神經生物標記市場：類型變異分析

5. 神經生物標記市場：細分分析、按應用，2018-2030 年

  • 神經生物標記市場：應用變異分析

6. 神經生物標記市場：細分分析、依最終用途，2018-2030 年

  • 神經生物標記市場：最終用途變異分析

7. 神經生物標記市場：區域細分分析，2018-2030

  • 區域市場概況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

8. 神經生物標記市場：競爭分析

  • 公司分類
  • 戰略地圖
    • 新產品發布
    • 夥伴關係
    • 獲得
    • 合作
    • 資金籌措
  • 2022年公司市場佔有率分析
  • 公司簡介
    • Abbott
    • Johnson & Johnson Services, Inc.
    • Bio-Rad Laboratories, Inc.
    • Alseres Pharmaceuticals, Inc.
    • Banyan Biomarkers, Inc.
    • Rules-Based Medicine
    • Thermo Fisher Scientific, Inc.
    • Diagenic Asa
    • Merck & Co., Inc.
    • Quanterix
Product Code: GVR-3-68038-823-7

Neurological Biomarkers Market Growth & Trends:

The global neurological biomarkers market size is expected to reach USD 18.75 billion by 2030, expanding at a CAGR of 12.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increased funding for R&D of neurological biomarkers to boost development of new drugs is expected to impel market growth. National Institute of Neurological Disorders and Stroke provides funding opportunities such as cooperative agreements & development grants for researchers conducting studies related to clinical validation, analytical validation, & biomarker discovery.

Biomarkers play a significant role in the development of drugs for the treatment of neurological diseases. In recent years, there has been a significant rise in investments in the R&D of treatments for neurological diseases. For instance, in December 2020, Target ALS-a nonprofit research foundation-announced research funding of USD 15 million for a project focused on the discovery of novel biomarkers for ALS, which is anticipated to accelerate market growth in the forecast period.

Availability of technologically advanced products such as Quanterix Simoa (single-molecule array), which is a digitized ELISA test with a high signal-to-noise ratio. This technology helps overcome blood-brain barrier issues associated with neurological disease-related biomarkers. Such technological advancements are expected to drive market growth. For instance, in January 2021, Abbott introduced the first rapid blood test for traumatic brain injury, including concussion. This test measures a particular protein that is found in the blood after a traumatic brain injury and can be used to rule out the need for CT scanning in case of negative test results.

Factors such as lack of awareness about such diagnostic products & their high cost and limited availability or absence of neurologists, especially in developing & underdeveloped countries, could affect the adoption of such biomarker-based diagnostic solutions. According to a World Federation of Neurology survey of 63/84 WHO member countries, the majority of neurologists in 31/63 countries worked in major cities. One neurologist was serving a population of about 6,240 to 4,750,000.

Neurological Biomarkers Market Report Highlights:

  • In 2024, proteomic type accounted for the largest market share and is anticipated to maintain their dominance over the forecast period as these are essential for accurate diagnosis of disease onset and progression due to the careful detection of posttranslational modifications and protein signatures
  • Parkinson's disease segment held the largest market share owing to rising incidence and increasing R&D activities.
  • Based on end use, the research organizations and others segment dominated the neurological biomarkers market. Research organizations collaborating for the development of therapeutics for treating neurological disorders utilize biomarkers for assessing the drug tolerance.
  • North America dominated the market owing to presence of market players with strong presence in the U.S. & Canada, and increasing government funding for the development of novel biomarkers
  • Asia-Pacific is anticipated to witness significant growth over the forecast period owing to high adoption of technologically advanced diagnostic products in developed countries such as Japan & Australia and increasing adoption of these products in developing economies such as China and India.

Table of Contents

Chapter 1 Methodology And Scope

  • 1.1 Market Segmentation And Scope
    • 1.1.1 Segment Definition
      • 1.1.1.1 Application Segment
      • 1.1.1.2 Type Segment
      • 1.1.1.3 End Use Segment
  • 1.2 Regional Scope
  • 1.3 Estimates And Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 Gvr's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Application And Type Snapshot
  • 2.3 End Use Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 Neurological Biomarkers Market Variables, Trends, And Scope

  • 3.1 Neurological Biomarkers Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
  • 3.2 Penetration And Growth Prospect Mapping
  • 3.3 Pipeline Analysis
    • 3.3.1 Alzheimer's Disease
    • 3.3.2 Parkinson's Disease
    • 3.3.3 Multiple Sclerosis
    • 3.3.4 Autism Spectrum Disorder
  • 3.4 Market Dynamics
    • 3.4.1 Market Driver Analysis
      • 3.4.1.1 Increasing Prevalence Of Neurological Diseases
      • 3.4.1.2 Technological Advancements
      • 3.4.1.3 Increased Funding For R&D In Biomarkers
    • 3.4.2 Market Restraint Analysis
      • 3.4.2.1 Lack Of Consumer Awareness
      • 3.4.2.2 Reimbursement Policies
  • 3.5 Neurological Biomarkers: Market Analysis Tools
    • 3.5.1 Industry Analysis - Porter's
    • 3.5.2 Pestle Analysis

Chapter 4 Neurological Biomarkers Market: Segment Analysis, By Type, 2018 - 2030 (USD Million)

  • 4.1 Neurological Biomarkers Market: Type Movement Analysis
    • 4.1.1 Genomic
      • 4.1.1.1 Genomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.2 Proteomic
      • 4.1.2.1 Proteomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.3 Metabolomic
      • 4.1.3.1 Metabolomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.5 Imaging
      • 4.1.5.1 Imaging Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.6 Others
      • 4.1.6.1 Others Neurological Biomarkers Market, 2018 - 2030 (USD Million)

Chapter 5 Neurological Biomarkers Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 5.1 Neurological Biomarkers Market: Application Movement Analysis
    • 5.1.1 Alzheimer's Disease
      • 5.1.1.1 Alzheimer's Disease Market, 2018 - 2030 (USD Million)
    • 5.1.2 Parkinson's Disease
      • 5.1.2.1 Parkinson's Disease Market, 2018 - 2030 (USD Million)
    • 5.1.3 Multiple Sclerosis
      • 5.1.3.1 Multiple Sclerosis Market, 2018 - 2030 (USD Million)
    • 5.1.4 Autism Spectrum Disorder
      • 5.1.4.1 Autism Spectrum Disorder Market, 2018 - 2030 (USD Million)
    • 5.1.5 Others
      • 5.1.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 Neurological Biomarkers Market: Segment Analysis, By End Use, 2018 - 2030 (USD Million)

  • 6.1 Neurological Biomarkers Market: End Use Movement Analysis
    • 6.1.1 Research Organizations
      • 6.1.1.1 Research Organizations Market, 2018 - 2030 (USD Million)
    • 6.1.2 Pharma & Biotech Companies
      • 6.1.2.1 Pharma & Biotech Companies Market, 2018 - 2030 (USD Million)
    • 6.1.3 Clinical Diagnostics
      • 6.1.3.1 Clinical Diagnostics Market, 2018 - 2030 (USD Million)

Chapter 7 Neurological Biomarkers Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

  • 7.1 Regional Market Snapshot
  • 7.2 North America
    • 7.2.1 North America Neurological Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.2.2 Key Country Dynamics
      • 7.2.2.3 Regulatory Framework
      • 7.2.2.4 Reimbursement Scenario
    • 7.2.3 Canada
      • 7.2.3.1 Canada Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.3.2 Key Country Dynamics
      • 7.2.3.3 Regulatory Framework
      • 7.2.3.4 Reimbursement Scenario
    • 7.2.4 Mexico
      • 7.2.4.1 Mexico Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.4.2 Key Country Dynamics
      • 7.2.4.3 Regulatory Framework
      • 7.2.4.4 Reimbursement Scenario
  • 7.3 Europe
    • 7.3.1 Europe Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.2 Uk
      • 7.3.2.1 Uk Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.2.2 Key Country Dynamics
      • 7.3.2.3 Regulatory Framework
      • 7.3.2.4 Reimbursement Scenario
    • 7.3.3 Germany
      • 7.3.3.1 Germany Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.3.2 Key Country Dynamics
      • 7.3.3.3 Regulatory Framework
      • 7.3.3.4 Reimbursement Scenario
    • 7.3.4 Spain
      • 7.3.4.1 Spain Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.4.2 Key Country Dynamics
      • 7.3.4.3 Regulatory Framework
      • 7.3.4.4 Reimbursement Scenario
    • 7.3.5 France
      • 7.3.5.1 France Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.5.2 Key Country Dynamics
      • 7.3.5.3 Regulatory Framework
      • 7.3.5.4 Reimbursement Scenario
    • 7.3.6 Italy
      • 7.3.6.1 Italy Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.6.2 Key Country Dynamics
      • 7.3.6.3 Regulatory Framework
      • 7.3.6.4 Reimbursement Scenario
    • 7.3.7 Denmark
      • 7.3.7.1 Denmark Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.7.2 Key Country Dynamics
      • 7.3.7.3 Regulatory Framework
      • 7.3.7.4 Reimbursement Scenario
    • 7.3.8 Sweden
      • 7.3.8.1 Sweden Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.8.2 Key Country Dynamics
      • 7.3.8.3 Regulatory Framework
      • 7.3.8.4 Reimbursement Scenario
    • 7.3.9 Norway
      • 7.3.9.1 Norway Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.9.2 Key Country Dynamics
      • 7.3.9.3 Regulatory Framework
      • 7.3.9.4 Reimbursement Scenario
  • 7.4 Asia Pacific
    • 7.4.1 Asia-Pacific Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.2 Japan
      • 7.4.2.1 Japan Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.2.2 Key Country Dynamics
      • 7.4.2.3 Regulatory Framework
      • 7.4.2.4 Reimbursement Scenario
    • 7.4.3 China
      • 7.4.3.1 China Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.3.2 Key Country Dynamics
      • 7.4.3.3 Regulatory Framework
      • 7.4.3.4 Reimbursement Scenario
    • 7.4.4 India
      • 7.4.4.1 India Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.4.2 Key Country Dynamics
      • 7.4.4.3 Regulatory Framework
      • 7.4.4.4 Reimbursement Scenario
    • 7.4.5 South Korea
      • 7.4.5.1 South Korea Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.5.2 Key Country Dynamics
      • 7.4.5.3 Regulatory Framework
      • 7.4.5.4 Reimbursement Scenario
    • 7.4.6 Thailand
      • 7.4.6.1 Thailand Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.6.2 Key Country Dynamics
      • 7.4.6.3 Regulatory Framework
      • 7.4.6.4 Reimbursement Scenario
    • 7.4.7 Australia
      • 7.4.7.1 Australia Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.7.2 Key Country Dynamics
      • 7.4.7.3 Regulatory Framework
      • 7.4.7.4 Reimbursement Scenario
  • 7.5 Latin America
    • 7.5.1 Latin America Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.5.2.2 Key Country Dynamics
      • 7.5.2.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
    • 7.5.3 Argentina
      • 7.5.3.1 Argentina Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.5.3.2 Key Country Dynamics
      • 7.5.3.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
  • 7.6 MEA
    • 7.6.1 MEA Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.2.2 Key Country Dynamics
      • 7.6.2.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.3.2 Key Country Dynamics
      • 7.6.3.3 Regulatory Framework
      • 7.6.3.4 Reimbursement Scenario
    • 7.6.4 UAE
      • 7.6.4.1 UAE Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.4.2 Key Country Dynamics
      • 7.6.4.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.5 Kuwait
      • 7.6.5.1 Kuwait Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.5.2 Key Country Dynamics
      • 7.6.5.3 Regulatory Framework
      • 7.6.5.4 Reimbursement Scenario

Chapter 8 Neurological Biomarkers Market: Competitive Analysis

  • 8.1 Company Categorization
  • 8.2 Strategy Mapping
    • 8.2.1 New Product Launch
    • 8.2.2 Partnerships
    • 8.2.3 Acquisition
    • 8.2.4 Collaboration
    • 8.2.5 Funding
  • 8.3 Company Market Share Analysis, 2022
  • 8.4 Company Profiles
    • 8.4.1 Abbott
      • 8.4.1.1 Company Overview
      • 8.4.1.2 Financial Performance
      • 8.4.1.3 Product Benchmarking
      • 8.4.1.4 Strategic Initiatives
    • 8.4.2 Johnson & Johnson Services, Inc.
      • 8.4.2.1 Company Overview
      • 8.4.2.2 Financial Performance
      • 8.4.2.3 Product Benchmarking
      • 8.4.2.4 Strategic Initiatives
    • 8.4.3 Bio-Rad Laboratories, Inc.
      • 8.4.3.1 Company Overview
      • 8.4.3.2 Financial Performance
      • 8.4.3.3 Product Benchmarking
      • 8.4.3.4 Strategic Initiatives
    • 8.4.4 Alseres Pharmaceuticals, Inc.
      • 8.4.4.1 Company Overview
      • 8.4.4.2 Product Benchmarking
    • 8.4.5 Banyan Biomarkers, Inc.
      • 8.4.5.1 Company Overview
      • 8.4.5.2 Product Benchmarking
      • 8.4.5.3 Strategic Initiatives
    • 8.4.6 Rules-Based Medicine
      • 8.4.6.1 Company Overview
      • 8.4.6.2 Financial Performance
      • 8.4.6.3 Product Benchmarking
      • 8.4.6.4 Strategic Initiatives
    • 8.4.7 Thermo Fisher Scientific, Inc.
      • 8.4.7.1 Company Overview
      • 8.4.7.2 Financial Performance
      • 8.4.7.3 Product Benchmarking
      • 8.4.7.4 Strategic Initiatives
    • 8.4.8 Diagenic Asa
      • 8.4.8.1 Company Overview
      • 8.4.8.2 Product Benchmarking
    • 8.4.9 Merck & Co., Inc.
      • 8.4.9.1 Company Overview
      • 8.4.9.2 Financial Performance
      • 8.4.9.3 Product Benchmarking
      • 8.4.9.4 Strategic Initiatives
    • 8.4.10 Quanterix
      • 8.4.10.1 Company Overview
      • 8.4.10.2 Product Benchmarking
      • 8.4.10.3 Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 3 North America neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 U.S. neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 7 U.S. neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 Canada neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 10 Canada neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 11 Mexico neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 12 Mexico neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 13 Mexico neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 Europe neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 15 Europe neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 16 Europe neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 17 UK neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 18 UK neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 19 UK neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 Germany neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 21 Germany neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 22 Germany neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 23 France neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 24 France neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 25 France neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Italy neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 27 Italy neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 28 Italy neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 29 Spain neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 30 Spain neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 31 Spain neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 32 Denmark neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 33 Denmark neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 34 Denmark neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 Sweden neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 36 Sweden neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 37 Sweden neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 38 Norway neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 39 Norway neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 40 Norway neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 44 Japan neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 45 Japan neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 46 Japan neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 China neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 48 China neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 49 China neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 India neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 51 India neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 52 India neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 South Korea neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 54 South Korea neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 55 South Korea neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 Australia neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 57 Australia neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 58 Australia neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Thailand neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 60 Thailand neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 61 Thailand neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Latin America neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 63 Latin America neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 64 Latin America neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 65 Brazil neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 66 Brazil neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 67 Brazil neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 68 Argentina neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 69 Argentina neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 70 Argentina neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 71 MEA neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 72 MEA neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 73 MEA neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 74 South Africa neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 75 South Africa neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 76 South Africa neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 77 Saudi Arabia neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 78 Saudi Arabia neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 79 Saudi Arabia neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 80 UAE neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 81 UAE neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 82 UAE neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 83 Kuwait neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 84 Kuwait neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 85 Kuwait neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Neurological biomarkers market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot (Type and application)
  • Fig. 11 Segment snapshot (End-use)
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Biomarkers market value, 2022 (USD Million)
  • Fig. 14 Neurological biomarkers market dynamics
  • Fig. 15 Prevalence of Alzheimer's disease by age group, 2024
  • Fig. 16 Neurological biomarkers market: PORTER's analysis
  • Fig. 17 Neurological biomarkers market: PESTLE analysis
  • Fig. 18 Neurological biomarkers market: Type outlook and key takeaways
  • Fig. 19 Neurological biomarkers market: Type movement analysis
  • Fig. 20 Genomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Proteomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Metabolomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Imaging market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Other neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Neurological biomarkers market: Application outlook and key takeaways
  • Fig. 26 Neurological biomarkers market: Application movement analysis
  • Fig. 27 Alzheimer's disease market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Parkinson's disease market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Multiple sclerosis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Autism spectrum disorder market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Neurological biomarkers market: End-use outlook and key takeaways
  • Fig. 33 Neurological biomarkers market: End-use movement analysis
  • Fig. 34 Research Organizations market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Pharma & Biotech Companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Clinical Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Neurological biomarkers market revenue, by region, 2022 & 2030 (USD Million)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 U.S. neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Target disease prevalence
  • Fig. 44 Key country dynamics
  • Fig. 45 Canada neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Target disease prevalence
  • Fig. 47 Europe neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 UK neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Germany neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Target disease prevalence
  • Fig. 53 Key country dynamics
  • Fig. 54 France neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Italy neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Spain neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Denmark neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Sweden neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Norway neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Target disease prevalence
  • Fig. 66 Rest of Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Japan neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Target disease prevalence
  • Fig. 71 Key country dynamics
  • Fig. 72 China neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 India neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Target disease prevalence
  • Fig. 76 Key country dynamics
  • Fig. 77 Australia neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Thailand neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Korea neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Rest of Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Latin America neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Brazil neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Mexico neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Argentina neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Rest of Latin America neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 MEA neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 South Africa neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Target disease prevalence
  • Fig. 95 Key country dynamics
  • Fig. 96 Saudi Arabia neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Target disease prevalence
  • Fig. 98 Key country dynamics
  • Fig. 99 UAE neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Target disease prevalence
  • Fig. 101 Key country dynamics
  • Fig. 102 Kuwait neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Target disease prevalence
  • Fig. 104 Key payors in Kuwait
  • Fig. 105 Rest of MEA neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Key company categorization
  • Fig. 107 Company market positioning
  • Fig. 108 Company market share analysis, 2022
  • Fig. 109 Strategic framework